Author of

• 31932

  +

  EP1.04 - Immuno-oncology (ID 194)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Immuno-oncology
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 31977

    +

    EP1.04-40 - Extra-Thoracic Metastasis Indicated Worse Clinical Efficacy on Immune Checkpoint Inhibitors in Chinese Advanced NSCLC Patients (Now Available) (ID 995)

    08:00 - 18:00  |  Presenting Author(s): Sangtian Liu
    • Abstract
    • Slides

    Background
    

    Immune checkpoint inhibitors (ICIs) have demonstrated inspiring effectiveness against lots of cancer types, including non-small-cell lung cancer (NSCLC). However, the individual therapeutic response varies and heterogeneous. The purpose of this study was to investigate the association of different metastatic sites with clinical outcomes after ICIs monotherapy in Chinese advanced NSCLC patients.

    Method
    

    We retrospectively analyzed all patients receiving more than two circles of ICIs monotherapy (anti-programmed death 1 or anti-PD-L1) in Shanghai pulmonary hospital from January 2016 to December 2018. Detailed clinical characteristics, metastasis status and progress-free survival (PFS, calculated from the first day receiving ICIs until the disease progressed) was recorded.

    Result
    

    76 patients were enrolled in this study. 10 of them received immunotherapy in the first-line and 46 of them in the second-line. The rate of extra-thoracic metastasis was 50% (38/76), including brain metastasis (10/38), liver metastasis (11/38), bone marrow metastasis (30/38), adrenal metastasis (4/38), extra-thoracic lymph node metastasis (10/38) and others (5/38). Patients with extra-thoracic metastasis had a significantly shorter PFS than those without (median PFS 4.20 VS 7.10months; hazard ratio [HR] 1.939, 95% CI 1.221-3.389; p=0.0072). In subgroup analysis, patients with brain metastasis, liver metastasis or bone marrow metastasis showed significantly shorter PFS than those without (3.35 vs 4.60m, p=0.0499; 2.50 vs 4.60m, p=0.0007; 3.70 vs 5.80m, p=0.0003 respectively). The disease control rate (DCR) is numerically lower in patients with extra-thoracic metastasis (66.7% vs 80%) comparing with those without, even though not statistically significant.

    Conclusion
    

    The current study suggested that advanced NSCLC patients with extra-thoracic metastasis indicated worse clinical outcomes on ICIs monotherapy and more clinical strategies should be considered to improving treatment efficacy for them.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.